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Penicillin-binding protein 5 (PBP 5) of Escherichia
coli functions as a D-alanine carboxypeptidase, cleaving
the C-terminal D-alanine residue from cell wall peptides.
Like all PBPs, PBP 5 forms a covalent acyl-enzyme com-
plex with b-lactam antibiotics; however, PBP 5 is distin-
guished by its high rate of deacylation of the acyl-en-
zyme complex (t1⁄2 ; 9 min). A Gly-1053 Asp mutation in
PBP 5 markedly impairs this b-lactamase activity
(deacylation), with only minor effects on acylation, and
promotes accumulation of a covalent complex with pep-
tide substrates. To gain further insight into the catalytic
mechanism of PBP 5, we determined the three-dimen-
sional structure of the G105D mutant form of soluble
PBP 5 (termed sPBP 5*) at 2.3 Å resolution. The struc-
ture is composed of two domains, a penicillin binding
domain with a striking similarity to Class A b-lactama-
ses (TEM-1-like) and a domain of unknown function. In
addition, the penicillin-binding domain contains an ac-
tive site loop spatially equivalent to the V loop of b-lac-
tamases. In b-lactamases, the V loop contains two amino
acids involved in catalyzing deacylation. This similarity
may explain the high b-lactamase activity of wild-type
PBP 5. Because of the low rate of deacylation of the
G105D mutant, visualization of peptide substrates
bound to the active site may be possible.
Penicillin and other b-lactam antibiotics exert their lethal
effect by inhibiting the proteins that synthesize bacterial cell
wall peptidoglycan (1). These proteins, known as penicillin-
binding proteins or PBPs,1 utilize lipid-linked disaccharide
peptide substrates to catalyze both the polymerization of gly-
can chains (transglycosylation) and cross-linking of peptide
chains (transpeptidation) during cell wall synthesis. In the
latter reaction, a serine residue on the PBP reacts with the
acyl-D-Ala-D-Ala C terminus of the peptide chain to form a
transient acyl-enzyme complex, releasing the C-terminal D-
alanine residue. This complex reacts with an amino group from
another peptide chain to form a cross-link, which is crucial to
the integrity and rigidity of the cell wall. An additional activity
catalyzed by some PBPs, carboxypeptidation, occurs when the
acyl-enzyme complex reacts with water. Penicillin and other
b-lactam antibiotics mimic the structure of the acyl-D-Ala-D-Ala
C terminus of the peptide chain (2) and react with PBPs to form
an acyl-enzyme complex. Unlike the transient nature of the
PBP-peptide complex, the acyl-enzyme complex formed be-
tween PBPs and b-lactam antibiotics is much more stable and
results in prolonged inhibition of the enzyme.
In Escherichia coli, at least 10 PBPs have been identified.
These PBPs can be split into two classes: the high molecular
mass PBPs (PBPs 1A, 1B, 1C, 2, and 3) and the low molecular
mass PBPs (PBPs 4, 5, 6, 6b, and 7) (3). High molecular mass
PBPs are essential for cell viability and are involved in the
physiological processes of cell elongation, cell division, and the
maintenance of cell shape (4). The role of low molecular mass
PBPs in bacterial physiology is less clear. These PBPs catalyze
D,D-endopeptidase or D,D-carboxypeptidase activity both in
vitro and in vivo (5, 6), but although they account for .90% of
the amount of penicillin G bound to membranes, they are not
essential for cell viability (7). However, a recent study utilizing
strains with multiple deletions of low molecular mass
PBPs revealed a role for PBP 5 in the proper synthesis of
peptidoglycan (8).
Production of a b-lactamase is the most common mechanism
by which bacteria become resistant to b-lactam antibiotics (9).
The initial step of the reaction catalyzed by these enzymes is
analogous to that mediated by PBPs, but instead of accumu-
lating a stable acyl-enzyme complex, b-lactamases destroy the
antibiotic by rapidly hydrolyzing the acyl-enzyme bond. Anal-
ysis of the sequences and crystal structures of PBPs and Class
A and class C b-lactamases reveals strong structural similari-
ties in the two classes of penicillin-interacting proteins (10–
12). The hallmark of all active site serine-based penicillin-
interacting proteins is the presence of three well conserved
motifs in the active site (13). These motifs are the SXXK tetrad
containing the active site serine residue, the (S/Y)XN triad, and
the KT(S)G triad.
The reaction mechanism of the interaction of b-lactam anti-
biotics with PBPs and b-lactamases is represented schemati-








E 1 P (Eq. 1)
where E is the PBP or b-lactamase, S is a b-lactam antibiotic,
E z S is the Michaelis complex, E-S* is the covalent acyl-enzyme
complex, and P is the inactive degradation product (14, 15). In
PBPs, k3 is usually quite small compared with k2, leading to
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accumulation of the inactive acylated enzyme. For b-lactama-
ses, both the k2 and k3 rate constants are very large, and the
b-lactam antibiotic is hydrolyzed.
In contrast to most other PBPs, E. coli PBP 5 is distinguished
by its high b-lactamase activity, with k3 ' 0.07 s
21 (t1⁄2 , 10
min) for the penicilloyl-PBP 5 complex. A mutant PBP 5, PBP
5-G105D (termed PBP 59), shows near normal acylation rates
with penicillin G but displays a 30-fold decrease in the rate of
deacylation (16, 17). Additionally, the mutant protein forms a
stable covalent complex with the depsipeptide substrate, N,N9-
diacetyl-L-lysyl-D-alanyl-D-lactate, which is not observed with
the wild-type protein (16). The phenotype of PBP 59 is similar
to that of wild-type PBP 5 in which Cys-115 has been modified
with sulfhydryl reagents, causing a larger effect on deacylation
than acylation (18). However, since the mutants PBP 5-C115A
and PBP 5-C115S both display wild-type levels of D-alanine
carboxypeptidase (CPase) and penicillin binding activities, this
residue does not appear to be directly involved in the catalytic
mechanism of the enzyme (17). Subsequent attempts to iden-
tify residues involved in deacylation of PBP 5 have been un-
successful (19).
In an effort to understand the molecular mechanism of
deacylation of PBP 5 and to define further the interactions of
b-lactam antibiotics and peptide substrates with PBPs, we
have solved the structure of the G105D mutant of PBP 5 at
2.3-Å resolution, the first structure for PBP 5. It reveals the
closest similarity yet identified between a PBP-type enzyme
and a Class A b-lactamase, which may explain the relatively
high b-lactamase activity of PBP 5.
MATERIALS AND METHODS
Protein Purification and Crystallization—Construction of the expres-
sion plasmid encoding sPBP 59 has been described (17, 20). The gene
encoding the G105D mutant form of PBP 5 missing its last 17 codons
(plus six extra codons added during plasmid construction) was cloned
into the PstI-HindIII restriction sites of pBR322. Overnight cultures of
MC1061 harboring the expression plasmid were subjected to osmotic
shock (21), and sPBP 59 was purified from the shock fluid by ampicillin
affinity chromatography exactly as described (17). The purified protein
was dialyzed exhaustively against 20 mM Trisz HCl, 150 mM NaCl, 10
mM 2-mercaptoethanol, 0.2% NaN3, pH 7.5 and concentrated to 6–8 mg
ml21. SDS-polyacrylamide electrophoresis indicated that the protein
was .98% pure with very little of the characteristic 30- and 10-kDa
breakdown products (22).
Crystallization conditions were similar to those described previously
(23). Crystals were grown by vapor diffusion in 20% polyethylene glycol
4000, 50 mM TriszHCl, pH 7.0, 0.2% NaN3. Crystals of bullet-shaped
morphology formed at 18 °C within 1–2 days. The crystals belong to
space group P32 with cell dimensions a 5 50.83 Å and b 5 c 5 140.29
Å. There is one molecule in the asymmetric unit.
Data Collection—In all cases crystals were mounted in quartz capil-
laries, and data were collected at room temperature by the standard
oscillation method. The initial native data set was collected using a
Rigaku RAXIS-II image plate system (Molecular Structures Corp., The
Woodlands, TX) mounted on a Rigaku RU-300 x-ray generator operat-
ing at 40 kV and 80 mA and fitted with a graphite monochromator. The
crystal-to-plate distance was 130 mm, the oscillation angle was 3°, and
the exposure time was 30 min frame21. A total of 84° of data was
collected.
Derivative diffraction data were collected using a DIP 2030H image
plate detector mounted on a Nonius FR391 rotating anode x-ray gen-
erator fitted with MacScience focusing mirrors (Nonius B. V., Delft, The
Netherlands) and operating at 40 kV and 100 mA. Data were collected
at a crystal-to-plate distance of 150 mm, with an oscillation angle of 1°
and an exposure time of 18 min frame21. Rotation ranges of 60–75°
were sufficient to collect essentially complete data sets.
For model refinement purposes a high resolution data set was col-
lected, where the crystal-to-plate distance was 150 mm, the oscillation
angle was 1°, and the exposure time was 12 min frame21. To ensure a
high redundancy of data, the crystal was rotated through a total of 90°.
In all cases the oscillation data were processed using HKL (24). In the
case of derivative data, the Friedel pairs were not merged in order to
retain the anomalous signal.
Phasing—A search for derivatives was made by soaking crystals in
solutions of heavy atom compounds in stabilizing buffer (20% polyeth-
ylene glycol 4000 in 100 mM TriszHCl, pH 7.0). Soaks in various mercury
and platinum compounds yielded several promising derivatives, as
judged by difference Patterson maps. In each case heavy atom positions
TABLE I
Data collection statistics
Hg(CN)2, mercury (II) cyanide; PIP, di-m-iodobis(ethylenediamine)
di-platinum nitrate.
Native 1 Native 2 Hg(CN)2 PIP
Molarity (mM) 1 10/sat.
Length of soak 2 d 1 h
Temperature (K) 298 298 298 298
Reflections (unique) 13776 17239 13482 9584
Reflections (measured) 37497 43406 34123 18341
Completeness (%) 98.0 94.8 95.6 95.9
Resolution (Å) 2.5 2.3 2.5 2.8
RSYM




, where Il is the intensity of the measured reflec-
tion, and IM is the mean intensity of all symmetry-related reflections.
TABLE II
Phasing statistics
Derivative abbreviations are as in Table I.
Derivative Hg(CN)2 PIP
Type of data Isomorphous Anomalous Isomorphous Anomalous
Resolution 2.5 2.5 2.8 2.8
No. of reflections 7246 5863 5182 4003
RMERGE
a 20.3 6.5
Phasing powerb 1.28 0.91 1.43 0.70
RCULLIS
c 0.849 0.946 0.777 0.971
RKRAUT
d 0.203 0.514 0.132 0.577
Overall figure of merit:
Before solvent flattening 0.244
















. FP, FPH, and FH are the protein, derivative, and heavy atom structure factors, respectively, and Er.m.s. is the
residual lack of closure.
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were determined and refined, and the data were used in trial phasing.
These calculations showed that two derivatives, mercury cyanide
(HgCN2) and di-m-iodobis-(ethylenediamine) di-platinum nitrate (PIP),
were of the best quality and sufficient to solve the structure. All calcu-
lations to this point were performed using PHASES (25). At this stage
the derivative and native data were merged using SCALEIT (26), and
the final phasing calculation was performed using SHARP (27) and
included anomalous data. The resulting multiple isomorphous replace-
ment (MIR) phases were improved by solvent flattening using SOLO-
MON (28) with an estimated solvent content of 46%.
Model Building and Refinement—An MIR electron density map (Fig.
1B) was calculated using CCP4 programs (26) and displayed using the
program O (29). The map was of excellent quality and was easily
interpreted to build the entire structure, including side chains, with the
exception of residues 1–3 and 74–90. The model was then refined by
alternating rounds of XPLOR and manual revision using O. In later
rounds water molecules were included. The final round of refinement
was performed using REFMAC (26). The stereochemistry of the final
model was evaluated using PROCHECK (30). The numbering of the




The structure of sPBP 59 was determined by MIR with anom-
alous scattering. The data collection and phasing statistics are
shown in Tables I and II, and portions of both the MIR and final
2/Fo 2 Fc electron density maps are shown in Fig. 1. The final
structure has an R factor of 19.6% (Rfree 5 27.0%) at 2.3-Å
resolution (Table III). Currently 151 water molecules are in-
cluded in the model.
As defined by PROCHECK (30), 90.0% of the residues lie
within the most favored region of the Ramachandran plot.
Three residues fall within disallowed regions. Of these, Ala-155
and Lys-219 both lie within loop regions with weak density,
whereas Ile-212 is a hydrophobic core residue with excellent
density. Residues with the highest B factors are located exclu-
sively at the termini or in surface-exposed loops. Certain parts
of the molecule have been omitted from the model where they
correspond to regions of poor electron density, likely due to
disorder. These are residues 1–3 at the N terminus, seven
residues at the C terminus (six of which are non-native and
result from the genetic construct), and an external loop com-
prising residues 74–90. The apparent flexibility of these latter
residues is consistent with the increased susceptibility of the
G105D mutant enzyme to proteolysis compared with PBP 5
wild type. Proteolysis of sPBP 59 generates characteristic 30-
and 10-kDa fragments by cleavage between residues 87 and 88,
which reside within this external loop (31).
Structure Description
sPBP 59 is composed of two domains that are oriented ap-
proximately at right angles to each other (Fig. 2). Each domain
is formed from contiguous primary sequence, residues 3 to 262
for domain 1 and residues 263 to 356 for domain 2. The N-
terminal region of sPBP 59 is a loop that extends away from
domain 1 and makes a slight contact with domain 2 via Lys-6.
Domain 1—The principal feature of domain 1 is a five-
stranded anti-parallel b sheet that forms the hydrophobic core.
This is packed on one side by an extended loop at the N
terminus, a10, and a loop connecting b8 and b9 that contains a
small a helix (a9). The other side is comprised primarily of an
array of seven a helices. In addition, there are three b hairpin-
like structures, b3-b4, b5-b6, and b7-b8, one of which (b3-b4)
contains the disordered residues 74–90. The active site of PBP
FIG. 1. Stereoviews of the electron
density maps of sPBP 5*. A, the sol-
vent-flattened MIR map at 2.5-Å resolu-
tion. B, the 2/Fo 2 Fc calculated phased
map generated from the final refined co-
ordinates at 2.3 Å. The region shown is a
portion of the hydrophobic core in domain
1. Both maps are contoured at 1 s and are
displayed using O (29).
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5 is located within this domain at the boundary of the five-
stranded b-sheet and the helical array (see below). It is imme-
diately apparent that domain 1 has the same fold as Class A
and Class C b-lactamases (discussed below).
Domain 2—This domain, which is almost exclusively com-
prised of b structure, is a sandwich of two anti-parallel b
sheets, one three-stranded and the other two-stranded. The
two-stranded sheet is kinked at residues Gly-272 and Asp-293,
causing the two sides of the sheet to be at right angles. The
effect of this is to form a loose b barrel at the C-terminal end of
the domain. Compared with domain 1, domain 2 has a rela-
tively hydrophobic surface as judged by an electrostatic plot
(data not shown), although none of these hydrophobic residues
are particularly well conserved in other CPases. The signifi-
cance of this apparent hydrophobicity and the role of this
domain in the function of the protein are unknown. A search of
the Protein Data Bank using the DALI server (32) revealed no
genuine structural similarities to domain 2.
Domain Interface—Since the hydrophobic cores of domains 1
and 2 extend to include the domain interface and because this
region has comparatively low B factors, significant movements
between domains 1 and 2 seem unlikely, suggesting that the
relative juxtaposition of the two domains is conserved.
Sequence Alignment to Other CPases and
Secondary Structure Assignment
A Blast search of the GenBankTM data base with E. coli PBP
5 as a query sequence identified two other E. coli PBPs (PBP 6
and PBP 6b) and PBPs from Salmonella typhimurium and
Haemophilus influenzae as its closest matches. Alignment of
these PBPs is shown in Fig. 3 along with secondary structure
assignments from the three-dimensional structure of sPBP 59.
As expected, the regions of highest identity reside in and
around the conserved sequence motifs (shown in parentheses)
associated with the active site in domain 1: residues 42–53
(Ser44-X-X-Lys47), residues 110–114 (Ser110-X-Asn112), and
residues 210–217 (Lys213-Thr214-Gly215) (19). Two additional
highly conserved regions, comprising residues 149–154 and
195–203, also are located in close proximity to the active site
(see Fig. 4). In general, the residues in domain 2 are less
conserved than domain 1, and most of the conserved residues
are within the hydrophobic core.
Active Site
The location of the active site is readily identified by plotting
the conserved sequence motifs onto the sPBP 59 structure. In
common with other PBPs and b-lactamases, the active site is
located in the cleft between the five-stranded anti-parallel b
sheet and the large a helical cluster. As viewed in Fig. 2, the
entrance to the active site is at the opposite end of the molecule
from the C terminus and the membrane anchor (which is miss-
ing in our construct), in an ideal position to interact with cell
wall peptides. The architecture of active site (Fig. 4) is com-
prised of the following elements: helix a2 (yellow), containing
Ser-44 and Lys-47 of the SXXK tetrad; the turn between helices
a4 and a5 (green), containing Ser-110 and Asn-112 of the SXN
triad; and b9 (orange), the edge strand of the b sheet containing
Lys-213, Thr-214, and Gly-215 of the KT(S)G triad. In addition,
the loops between b5 and b6 and between b8 and a9 also
contribute residues to the active site. These include His-151,
present on the extended loop (blue) at the bottom of the cavity,
and Arg-198, located on the loop (purple) at the top of the
cavity. Both of these latter residues are conserved in related
CPases (Fig. 4). The identification of Ser-44, Lys-47, Ser-110,
Asn-112, and Lys-213 as active site residues is consistent with
data showing that mutation of any of these renders PBP 5
highly deficient or, in some cases, completely inactive in both
antibiotic binding and carboxypeptidation (19, 33).
The hydrogen-bonding network within the active site is ex-
tensive (Fig. 4). The e-NH2 group of Lys-47 plays a central role
in this network, forming hydrogen bonds with the hydroxyl
group of Ser-44, the amide carbonyl group of Asn-112, and the
backbone carbonyl groups from both Ser-110 and His-151. In
common with other penicillin-interacting enzymes, the e-NH2
group of Lys-213 forms a hydrogen bond with Ser-110. In
contrast to Class A b-lactamases, in which two structurally
conserved water molecules are typically observed within the
FIG. 2. The structure of sPBP 5*. The structure of sPBP 59 with
secondary structure assignments and the location of N and C termini
are shown. In this view, the cytoplasmic membrane is at the bottom of
the molecule, and the entrance to the active site is at the top. This figure
was produced with the program SPOCK (available on the World Wide
Web).
TABLE III
Statistics of the final model
Resolution range (Å) 15.0-2.3
Sigma cut-off applied 0.0
Number of reflections used in refinement 17,208
Percentage of reflections used in RFREE 10.0
Completeness of data in resolution range (%) 95.4
Number of protein atoms 2,597
Number of water molecules 151
R factor (%) 19.6
Free R factor (%) 27.0
r.m.s. deviations from ideal stereochemistry
Bond lengths (Å) 0.011
Bond angles (°) 2.936
Dihedrals (°) 24.73
Impropers (°) 2.552
Mean B factor (main chain) (Å3) 39.29
r.m.s. deviation in main chain B factor (Å3) 1.36
Mean B factor (side chains and waters) (Å3) 39.18
r.m.s. deviation in side chain B factors (Å3) 1.55
Ramachandran plot
Residues in most-favored region (%) 90.0
Residues in additionally allowed regions (%) 8.3
Residues in generously allowed regions (%) 0.7
Residues in disallowed regions (%) 0.1
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hydrogen bonding network (34), there are no visible water
molecules in the immediate vicinity of the active site. However,
further refinement and higher resolution data of sPBP 59 may
be necessary to firmly establish the presence or absence of
potential active site water molecules.
Structural Homology of sPBP 59 and TEM-1 b-Lactamase
One of the most outstanding features of the sPBP 59 struc-
ture is the similarity of domain 1 with the fold of Class A
b-lactamases, as represented by TEM-1 (35) and PC1 (36).
Notably, this structural similarity is considerably more pro-
nounced than previously reported PBP structures, namely the
Streptomyces R61 D,D-peptidase (37) and PBP 2x from Strepto-
coccus pneumoniae (38). The main chain atoms in the 209
residues of domain 1 of sPBP 59 composing the common ele-
ments of secondary structure of penicillin-interacting proteins
can be superimposed onto the PC1 b-lactamase fold (36) with
an r.m.s. deviation of 2.7 Å and the TEM-1 b-lactamase (39)
fold with an r.m.s. deviation of 2.5 Å.
The similarity of domain 1 of sPBP 59 and TEM-1 b-lacta-
mase is shown in Fig. 5. The most significant differences be-
tween the two structures are 1) the N-terminal helix of TEM-1
is replaced by an extended chain in sPBP 59, 2) the disordered
region between residues 74 and 90 in sPBP 59 is visible in
TEM-1 as a small helix with connecting loops, 3) the extended
loop (colored blue in Fig. 4, of sPBP 59 has a slightly different
conformation compared with its counterpart in TEM-1, the
so-called V loop, and 4) in sPBP 59 the connection between
helices a8 and a9 contains a large b hairpin, whereas the
equivalent connection in TEM-1, between helices a9 and a10, is
direct.
A comparable degree of similarity with Class A b-lactamases
was also observed in the recently determined structure of the
Streptomyces K15 D,D-transpeptidase (40). In fact, the K15 PBP
FIG. 3. Sequence alignment and secondary structure assignment. Alignment of the soluble, mature form of E. coli PBP 5 (Swiss Protein
Database accession P04287) with E. coli PBP 6 (P08506) and PBP 6b (P33013), H. influenzae PBP 5 (P44466), and S. typhimurium PBP 6b
(P37604). Conserved residues among all five PBPs are depicted in green. The active site serine is shown in red, the site of the mutation in sPBP
59 is marked with by a @, and the cysteine residue in PBP 5 that reacts with sulfhydryl reagents is marked by a (#). The secondary structure
assignments are shown below. The dashed line represents the disordered region 74–90. The first three residues and the last six residues (the latter
of which are non-native and a result of the genetic construct) of sPBP 59 have been omitted for clarity.
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and sPBP 59 are close structural relatives. Domain 1 of sPBP 59
can be superimposed onto the K15 PBP structure with an r.m.s.
deviation of 1.2 Å between common main chain atoms (212
residues). The main differences of note are that the part of the
K15 PBP structure equivalent to the disordered region in sPBP
59 (residues 74–90) is ordered and that the b7-b8 hairpin is
considerably longer in the K15 PBP structure (b2c-b2d), gen-
erating a four-stranded b sheet on the surface of the K15 PBP.
Unlike most other PBPs, the K15 PBP does not contain a
traditional hydrophobic transmembrane anchor. Thus, it has
been proposed that the b2c-b2d hairpin promotes the associa-
tion of the K15 PBP with the cell membrane (40), which may
explain its longer length.
The active site residues of sPBP 59 and TEM-1 b-lactamase
were aligned by the program LSQKAB (26) (Fig. 6). Ser-44,
Lys-47, Ser-110, Asn-112, and Lys-213 are all spatially con-
served with the corresponding residues in TEM-1 b-lactamase,
again emphasizing the extensive homology between these two
proteins. Although the extended V-like loop at the lower region
of the active site of sPBP 59 is similarly positioned to the V loop
of TEM-1, there are significant conformational differences be-
tween the two. This is important because in Class A b-lacta-
mases, the V loop contains two residues, Glu-166 and Asn-170,
that are critical for the rapid hydrolysis of the acyl-enzyme
complex (41, 42). By analogy, the V-like loop in PBP 5 (residues
147–157) may also contain similar residues responsible for
deacylation, thus explaining the high b-lactamase activity ob-
served in wild-type PBP 5 (see “Discussion”).
DISCUSSION
Here we report the structure of a soluble, mutant form of
PBP 59 solved to 2.3-Å resolution by x-ray crystallography. The
structure of sPBP 59 reveals two domains, a penicillin-binding
domain and a domain of unknown function. The fold of the
penicillin-binding domain is highly similar to Class A b-lacta-
mases, further emphasizing the close evolutionary relationship
between these two classes of penicillin-interacting proteins.
Catalytic Function—PBP 5 is a serine-based D-alanine car-
boxypeptidase that is functionally similar to the well studied
family of serine proteases. Although both PBP 5 and the serine
proteases proceed through formation of an acyl-enzyme inter-
mediate followed by deacylation of the acylated enzyme, they
have evolved distinctly different catalytic mechanisms. The
close structural similarity of sPBP 59 with Class A b-lactama-
ses suggests a common mechanism of acylation by b-lactam
antibiotics for the two classes of enzymes. In the light of the
structure of PBP 59, the potential roles in catalysis of the
conserved active site residues of PBP 5 can now be discussed.
Acylation of PBP 5 with b-Lactam Antibiotics and Peptide
Substrates—The acylation reaction comprises four steps: for-
mation of the non-covalent complex, nucleophilic attack, tetra-
hedral intermediate formation, and collapse to the acyl-en-
zyme. Mutational evidence has shown that, at least for
b-lactam antibiotics, a positive charge at position 213 is crucial
for formation of the acyl-enzyme complex (33), suggesting that
Lys-213 (of the KTG triad) interacts with the carboxylate group
on both b-lactam antibiotics and peptide substrates. Interest-
ingly, the equivalent residue in b-lactamases, Lys-234, has
been proposed to stabilize the transition state (43, 44). Since in
our structure the e-amino group of Lys-213 interacts via poten-
tial hydrogen bonds with the hydroxyl group of Ser-110 and the
carbonyl group of Asn-107, an alternative role of this residue
may be simply to maintain the correct active site architecture
rather than to interact with substrate directly. It is interesting
to note that mutation of Lys-213 to arginine has no effect on
penicillin binding and hydrolysis yet abolishes CPase activity
(33). Such a mutation would increase the distance between two
key components of the active site, b9 and the C-terminal end of
a4, by approximately 1 Å. This may lower the binding affinity
for peptide substrates, which presumably have a larger binding
footprint without affecting the smaller binding site for
penicillin.
Acylation starts by nucleophilic attack of the active site
Ser-44 (22) on the amide bond of the peptide substrate or
b-lactam ring. In serine proteases, the nucleophilicity of the
serine residue is activated by the so-called “charge-relay” sys-
tem involving a histidine and aspartic acid residue (45). In our
structure it is difficult to assess which of the surrounding
residues enhance the nucleophilicity of Ser-44. One possibility
is that the amino group of Lys-47, which is within hydrogen-
bonding distance of the Ser-44 hydroxyl, acts as a general base.
For this to occur, however, the active site environment must
promote the deprotonated state of the e-NH2 group, requiring a
reduction in its pKa of approximately 3 pH units. This might be
achieved via its hydrogen-bonding interactions with Asn-112
and the carbonyl groups of His-151 and Ser-110 (Fig. 4). An
alternative possibility is that the nucleophilicity of Ser-44 may
be enhanced by the dipole moment of the helix a2. The role of
the helix dipole has recently been suggested to increase the
nucleophilicity of the active site cysteine in b-ketoacyl-acyl
carrier protein synthase III, a bacterial enzyme that catalyzes
a Claisen condensation in type II fatty acid synthesis (46).
It is interestingly to note that one characterized mutation,
D175N, which abolishes CPase activity and decreases acylation
by 50-fold (19), probably acts indirectly by perturbing the pre-
cise arrangement of the active site rather than having a direct
role in catalysis as previously suggested. Our structure shows
that the effect of this mutation is to break a hydrogen bond
between the side chains of Asp-175 and Tyr-52, located at the
C-terminal end of helix a2, more than 20 Å from Ser-44. That
such a subtle change has such a large impact on activity is
evidence that the precise positioning of the N-terminal end of
a2, which contains Ser-44 and Lys-47, is critical for catalysis.
The developing negative charge on the carbonyl oxygen of the
tetrahedral intermediate is likely stabilized by an oxyanion
FIG. 4. Active site architecture of sPBP 5*. The active site is
formed by five structural elements (colored yellow, green, blue, purple,
and orange). Potential hydrogen bonds are denoted by the dashed lines.
Note the orientations of the imidazole side chain and backbone carbonyl
group of His-151 and the position of Arg-198. This figure was produced
using MOLSCRIPT (51).
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hole similar to that proposed for many other enzymes, includ-
ing serine proteases, b-lactamases, and other PBPs. In PBP 59
the oxyanion hole is potentially formed by backbone amide
groups of residues 214 and 216 from b9 and Ser-44 on a2.
Arg-198 is positioned above the active site and may also help
stabilize the intermediate.
Hydrolysis of the Acyl-Enzyme Complex—The close struc-
tural overlap of PBP 59 with Class A b-lactamases suggests
that the relatively high deacylation rate of the b-lactam-bound
PBP 5 may be mediated by the loop equivalent to the V loop in
Class A b-lactamases. In the latter, two residues on this loop,
Glu-166 and Asn-170, are intimately involved in the rapid
deacylation of the acyl-enzyme complex (42, 47). In particular,
Glu-166 is believed to activate a conserved water molecule that
attacks the carbonyl of the acyl-enzyme (41, 48). By analogy,
residues in the V-like loop of PBP 5 may also position a cata-
lytic water molecule that attacks the acyl-enzyme complex.
Candidate residues from the V-like loop include His-151 and
Asp-154, both of which are conserved in other CPases (Fig. 3)
and one of which, His-151, is close to the active site (Fig. 4).
However, in our structure of the deacylation-defective PBP 59,
neither of these side chains is sufficiently close to the active site
to interact directly with substrate or potential catalytic water
molecules (Fig. 4). An alternative mechanism for hydrolysis of
the acyl-enzyme complex is that the backbone carbonyl moiety
of His-151, which in our structure is hydrogen-bonded to
Lys-47 (Fig. 4), participates in deacylation simply by favorably
orienting a hydrolytic water molecule. This is supported by the
spatial equivalence of carbonyl group of His-151 in PBP 59 with
the carboxyl group of Glu-166 in TEM-1 (Fig. 6).
Further evidence that the V-like loop in PBP 59 may indeed
be involved in deacylation comes from studies of deacylation-
defective forms of PBP 5. In the G105D mutant, Gly-105 (small)
is replaced by aspartate (charged and bulky), which may dis-
rupt the packing of helix a4 with the adjacent 74–90 loop and
cause the apparent flexibility of the latter observed in our
crystal structure. In both Class A b-lactamases and the K15
D,D-transpeptidase, the equivalent loop is ordered and packs
against the counterparts of helices a4, a5, and the V-like loop
in sPBP 59. A second deacylation-defective PBP 5 is obtained
through modification of Cys-115 by para-chloromercuribenzo-
ate in the wild-type enzyme (18). This residue is located on
helix a5 and packs into the space between a2 and a4. Intro-
duction of such a bulky group would doubtless perturb this
close packing and may also affect the conformation of the
adjacent 74–90 loop. Thus it appears that a decrease in deacy-
lation may result from changes in the specific region of the
structure containing a4, a5, the 74–90 loop, and the V-like
loop. In the structure of wild-type PBP 5, it will be interesting
to note whether the 74–90 loop is more ordered and indeed
whether the conformation of the V-like loop is altered as a
result.
Relationship of sPBP 59 to b-Lactamases—The structural
homology between the Streptomyces R61 D,D-peptidase and
PC1 b-lactamase was noted as early as 1986 (11, 12), but the
similarity between sPBP 59 and TEM-1 b-lactamase is even
more pronounced. A comparable degree of similarity to Class A
b-lactamases also has been observed with the Streptomyces
K15 D,D-transpeptidase (40). It has been suggested that each of
the different classes of b-lactamases have evolved from various
classes of PBPs (49). Our data are entirely consistent with this
hypothesis.
The main structural difference between the penicillin bind-
ing domain of sPBP 59 and Class A b-lactamases is in the
sequence and conformation of the V loop, perhaps suggesting
that Class A b-lactamases evolved directly from a PBP 5-like
CPase. This would be logical because CPases already had a
relatively efficient hydrolysis mechanism for peptide sub-
strates. By incorporating two new amino acids on the V loop
and by removing residues specific for CPase activity, b-lacta-
FIG. 5. Structural homology of TEM-1 b-lactamase and the penicillin-binding domain of sPBP 5*. The view of sPBP 59 is similar to that
shown in Fig. 4. The penicillin-binding domain of sPBP 59 is comprised of residues 1–265. The positions of active site residues are shown by a l
along with their residue numbers. This figure was produced using the program SPOCK (available on the World Wide Web).
FIG. 6. Alignment of the active site residues of sPBP 5* and
TEM-1 b-lactamase. The active site residues of sPBP 59 and TEM-1
b-lactamase (39) were aligned with the program LSQKAB (26). Back-
bone residues from sPBP 59 are depicted in orange, and active site
amino acids are shown in red. In TEM-1 b-lactamase, backbone resi-
dues are yellow, and active site amino acids are green. The carbonyl
group of His-151 is also shown. This figure was produced using MOL-
SCRIPT (51).
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mases evolved a highly efficient hydrolysis mechanism and at
the same time altered their specificity toward b-lactam antibi-
otics and away from peptide substrates.
Role of Domain 2—The two-domain structure of PBP 5, in
which catalytic activity resides in domain 1, is consistent with
previous genetic studies showing that deletion of the protein
after residue 263 results in an enzyme with near wild-type
CPase activity and b-lactam antibiotic affinity (50). This, how-
ever, leaves the role of domain 2 unclear. One possibility is that
this domain mediates interactions with other cell wall-synthe-
sizing enzymes to recruit PBP 5 to areas of active cell wall
synthesis. Indeed, the all b structure of this domain may facil-
itate such interactions through hydrogen bonding across b
strands. In E. coli, the lytic transglycosylase, MltA, interacts
with several PBPs as well as the scaffolding protein, MipA (8),
suggesting the existence of a cell wall-synthesizing complex, of
which PBP 5 may be a part. Alternatively, domain 2 may
function simply as a linker to position the active site in domain
1 closer to the peptidoglycan layer, where it can interact with
cell wall peptides.
Conclusion—By solving the crystal structure of a deacyla-
tion-defective mutant, we have obtained the first structural
information for PBP 5. PBP 5 shares the same fold and has a
common active site architecture with the well studied Class A
b-lactamases. Inspection of this structure suggests that Lys-47
may act as the general base to promote the nucleophilicity of
Ser-44 during acylation. In contrast, the mechanism of deacy-
lation is less clear. However, solving the wild-type PBP 5 struc-
ture and comparing it to PBP 59 should provide significant
insight into how PBP 5 catalyzes hydrolysis of the acyl-enzyme
complex. These studies are in progress.
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